Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English
  • Spanish

Education

Medical School

Johns Hopkins University School of Medicine

1986, Baltimore, MD

Residency

Stanford University

1990, Stanford, CA

Residency

Boston Children's Hospital

1995, Boston, MA

Certifications

  • American Board of Psychiatry and Neurology (Child and Adolescent Psychiatry)
  • American Board of Psychiatry and Neurology (Psychiatry)

Professional History

Dr. Gonzalez serves as an expert for Psychology for Boston Children's Hospital Precision Medicine Service. For more information about the Precision Medicine Service please visit bostonchildrens.org/precisionmed.

Publications

  1. Reduced Cerebellar Volumes Associate with P300 Amplitude Attenuation in Children with Clinical High Risk for Psychosis and Early Onset Psychosis. Cerebellum. 2025 Mar 21; 24(3):69. View Abstract

  2. The Impact of Childhood Maltreatment on Central Pain Processing in Individuals With Psychosis. Bipolar Disord. 2025 Mar; 27(2):132-143. View Abstract

  3. Validation of an ICD-Code-Based Case Definition for Psychotic Illness Across Three Health Systems. Schizophr Bull. 2024 11 08; 50(6):1482-1488. View Abstract

  4. Characterization of pain and somatization and its relationship with psychopathology in early onset psychosis. J Psychiatr Res. 2024 Nov; 179:77-82. View Abstract

  5. Challenging Case: New-Onset Hallucinations and Developmental Regression in a Child with Autism Spectrum Disorder. J Dev Behav Pediatr. 2024 May-Jun 01; 45(3):e267-e270. View Abstract

  6. Heterogeneity of clinical symptomatology in pediatric patients at clinical high risk for psychosis. BMC Res Notes. 2024 Mar 26; 17(1):88. View Abstract

  7. Validation of an ICD-code-based case definition for psychotic illness across three health systems. medRxiv. 2024 Feb 29. View Abstract

  8. Children with Early-Onset Psychosis Have Increased Burden of Rare GRIN2A Variants. Genes (Basel). 2023 03 23; 14(4). View Abstract

  9. Burden Experienced by Primary Caregivers of Children With Psychotic Disorders and at Clinical High Risk for Psychosis. J Am Psychiatr Nurses Assoc. 2024 May-Jun; 30(3):518-531. View Abstract

  10. 16p13.11 deletion variants associated with neuropsychiatric disorders cause morphological and synaptic changes in induced pluripotent stem cell-derived neurons. Front Psychiatry. 2022; 13:924956. View Abstract

  11. Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder. Am J Psychiatry. 2022 11 01; 179(11):853-861. View Abstract

  12. Evaluation of a scalable online videogame-based biofeedback program to improve emotion regulation: A descriptive study assessing parent perspectives. Internet Interv. 2022 Apr; 28:100527. View Abstract

  13. Novel CAPN1 missense variants in complex hereditary spastic paraplegia with early-onset psychosis. Ann Clin Transl Neurol. 2022 04; 9(4):570-576. View Abstract

  14. Childhood maltreatment and its role in the development of pain and psychopathology. Lancet Child Adolesc Health. 2022 03; 6(3):195-206. View Abstract

  15. Association of Social Gaming with Well-Being (Escape COVID-19): A Sentiment Analysis. Am J Med. 2022 02; 135(2):254-257. View Abstract

  16. ITSN1: a novel candidate gene involved in autosomal dominant neurodevelopmental disorder spectrum. Eur J Hum Genet. 2022 01; 30(1):111-116. View Abstract

  17. A "Proof of Concept" Randomized Controlled Trial of a Video Game Requiring Emotional Regulation to Augment Anger Control Training. Front Psychiatry. 2021; 12:591906. View Abstract

  18. Early role for a Na+,K+-ATPase (ATP1A3) in brain development. Proc Natl Acad Sci U S A. 2021 06 22; 118(25). View Abstract

  19. Underrepresentation of Phenotypic Variability of 16p13.11 Microduplication Syndrome Assessed With an Online Self-Phenotyping Tool (Phenotypr): Cohort Study. J Med Internet Res. 2021 03 16; 23(3):e21023. View Abstract

  20. RCL1 copy number variants are associated with a range of neuropsychiatric phenotypes. Mol Psychiatry. 2021 05; 26(5):1706-1718. View Abstract

  21. P300 amplitude attenuation in high risk and early onset psychosis youth. Schizophr Res. 2019 08; 210:228-238. View Abstract

  22. Diagnostic Uncertainty in a Complex Young Man: Autism Versus Psychosis. J Dev Behav Pediatr. 2019 01; 40(1):72-74. View Abstract

  23. De novo variant of TRRAP in a patient with very early onset psychosis in the context of non-verbal learning disability and obsessive-compulsive disorder: a case report. BMC Med Genet. 2018 11 13; 19(1):197. View Abstract

  24. Young children with psychotic symptoms and risk for suicidal thoughts and behaviors: a research note. BMC Res Notes. 2018 Aug 10; 11(1):568. View Abstract

  25. Social impairment and social language deficits in children and adolescents with and at risk for psychosis. Schizophr Res. 2019 02; 204:304-310. View Abstract

  26. De novo ATP1A3 and compound heterozygous NLRP3 mutations in a child with autism spectrum disorder, episodic fatigue and somnolence, and muckle-wells syndrome. Mol Genet Metab Rep. 2018 Sep; 16:23-29. View Abstract

  27. Potentially traumatic events in youth with and at clinical high risk for psychosis. Early Interv Psychiatry. 2019 08; 13(4):805-809. View Abstract

  28. Suicidal behaviors and their relationship with psychotic-like symptoms in children and adolescents at clinical high risk for psychosis. Compr Psychiatry. 2017 10; 78:31-37. View Abstract

  29. Review of Salient Investigational Drugs for the Treatment of Fragile X Syndrome. J Child Adolesc Psychopharmacol. 2017 Dec; 27(10):850-863. View Abstract

  30. Social cognitive impairment in 22q11 deletion syndrome: A review. Psychiatry Res. 2017 07; 253:99-106. View Abstract

  31. A Developmental Perspective on Social-Cognition Difficulties in Youth at Clinical High Risk for Psychosis. Harv Rev Psychiatry. 2017 Jan/Feb; 25(1):4-14. View Abstract

  32. Suicidal behaviors in children and adolescents with psychotic disorders. Schizophr Res. 2017 01; 179:13-16. View Abstract

  33. A novel de novo mutation in ATP1A3 and childhood-onset schizophrenia. Cold Spring Harb Mol Case Stud. 2016 Sep; 2(5):a001008. View Abstract

  34. Overlapping 16p13.11 deletion and gain of copies variations associated with childhood onset psychosis include genes with mechanistic implications for autism associated pathways: Two case reports. Am J Med Genet A. 2016 May; 170A(5):1165-73. View Abstract

  35. N100 Repetition Suppression Indexes Neuroplastic Defects in Clinical High Risk and Psychotic Youth. Neural Plast. 2016; 2016:4209831. View Abstract

  36. Early auditory processing evoked potentials (N100) show a continuum of blunting from clinical high risk to psychosis in a pediatric sample. Schizophr Res. 2015 Dec; 169(1-3):340-345. View Abstract

  37. Neurophysiological differences between patients clinically at high risk for schizophrenia and neurotypical controls--first steps in development of a biomarker. BMC Med. 2015 Nov 02; 13:276. View Abstract

  38. Effect of 2 psychotherapies on depression and disease activity in pediatric Crohn's disease. Inflamm Bowel Dis. 2015 Jun; 21(6):1321-8. View Abstract

  39. Epilepsy & behavior: My intellectual home for 15 years! Epilepsy Behav. 2014 Nov; 40:96. View Abstract

  40. Comparing stimulant effects in youth with ADHD symptoms and epilepsy. Epilepsy Behav. 2014 Jul; 36:102-7. View Abstract

  41. Randomized efficacy trial of two psychotherapies for depression in youth with inflammatory bowel disease. J Am Acad Child Adolesc Psychiatry. 2014 Jul; 53(7):726-35. View Abstract

  42. "RAGE-Control": A Game to Build Emotional Strength. Games Health J. 2013 Feb; 2(1):53-7. View Abstract

  43. Management of psychotropic medication side effects in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2012 Oct; 21(4):713-38. View Abstract

  44. Elevated rates of ADHD in mothers of children with comorbid ADHD and epilepsy. Neuropsychiatry (London). 2012 Oct 01; 2(5):385-391. View Abstract

  45. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012 Sep 19; 4(152):152ra127. View Abstract

  46. Longitudinal results of cognitive behavioral treatment for youths with inflammatory bowel disease and depressive symptoms. J Clin Psychol Med Settings. 2012 Sep; 19(3):329-37. View Abstract

  47. Evidence-based treatment approach to autism spectrum disorders. Pediatr Ann. 2011 Nov; 40(11):569-74. View Abstract

  48. Tolerability of atomoxetine for treatment of pediatric attention-deficit/hyperactivity disorder in the context of epilepsy. Epilepsy Behav. 2011 Jan; 20(1):95-102. View Abstract

  49. The Use of Antiepileptic Drugs (AEDs) for the Treatment of Pediatric Aggression and Mood Disorders. Pharmaceuticals (Basel). 2010 Sep 10; 3(9):2986-3004. View Abstract

  50. Transcranial magnetic stimulation provides means to assess cortical plasticity and excitability in humans with fragile x syndrome and autism spectrum disorder. Front Synaptic Neurosci. 2010; 2:26. View Abstract

  51. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy Behav. 2010 Jul; 18(3):229-37. View Abstract

  52. Use of a virtual community as a psychosocial support system in pediatric transplantation. Pediatr Transplant. 2010 Mar; 14(2):261-7. View Abstract

  53. Association between attention-deficit/hyperactivity disorder and epilepsy in pediatric populations. Expert Rev Neurother. 2009 Dec; 9(12):1747-54. View Abstract

  54. RAGE Control: Regulate and Gain Emotional Control. Stud Health Technol Inform. 2009; 149:335-43. View Abstract

  55. Linkage analysis of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 05; 147B(8):1387-91. View Abstract

  56. Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder. J Psychiatr Pract. 2008 May; 14(3):160-9. View Abstract

  57. An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. Expert Opin Investig Drugs. 2008 Jan; 17(1):77-84. View Abstract

  58. Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav. 2008 Feb; 12(2):217-33. View Abstract

  59. Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder in children and adolescents. Evid Based Ment Health. 2007 May; 10(2):59. View Abstract

  60. Tolerability of selective serotonin reuptake inhibitors in thirty-nine children under age seven: a retrospective chart review. J Child Adolesc Psychopharmacol. 2007 Apr; 17(2):165-74. View Abstract

  61. Psychiatric disorders and behavioral characteristics of pediatric patients with both epilepsy and attention-deficit hyperactivity disorder. Epilepsy Behav. 2007 May; 10(3):384-8. View Abstract

  62. Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia. J Anxiety Disord. 2008; 22(1):88-97. View Abstract

  63. Pharmacological management of a youth with ADHD and a seizure disorder. J Am Acad Child Adolesc Psychiatry. 2006 Dec; 45(12):1527-32. View Abstract

  64. A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. J Psychiatr Pract. 2006 Jul; 12(4):214-22. View Abstract

  65. Depression experience journal: a computer-based intervention for families facing childhood depression. J Am Acad Child Adolesc Psychiatry. 2006 Feb; 45(2):158-165. View Abstract

  66. A Comparison of Divalproex and Risperidone in Pediatric Bipolar Disorder. Presented at the U.S. Psychiatric and Mental Health Congress. 2005.

  67. Tolerability of Olanzapine and Ziprasidone in Youths with Bipolar Disorder. Presented at the U.S. Psychiatric and Mental Health Congress. 2005.

  68. Tolerability of OROS-MPH 18 mg, 36 mg, and 54 mg in Pediatric Epilepsy Plus Attention-Deficit/Hyperactivity Disorder (ADHD). Presented at the American Academy of Child and Adolescent Psychiatry meeting. 2005.

  69. Tolerability of OROS-MPH 18 mg, 36 mg, and 54 mg in Pediatric Epilepsy Plus Attention-Deficit Hyperactivity Disorder (ADHD). Presented at the Child Neurology Society meeting. 2005.

  70. Tolerability of OROS-MPH 18 mg, 36 mg, and 54 mg in Pediatric Epilepsy Plus Attention-Deficit/Hyperactivity Disorder (ADHD). Presented at the International League Against Epilepsy meeting. 2005.

  71. A Comparison of Divalproex and Oxcarbazepine in Aggressive Youth with Bipolar Disorder. Presented at the Society for Biological Psychiatry meeting. 2005.

  72. Antiepileptic Drugs (AEDs) in the Treatment of Aggression in Children and Adolescents. Child and Adolescent Psychopharmacology News. 2005; 10(1):6-12.

  73. Psychopharmacology. . Behavioral and Developmental Pediatrics, A Handbook for Primary Care, Editors S Parker, B Zuckerman and M Augustyn. 2005; 83-89.

  74. Ziprasidone in Pediatric Patients: Efficacy and Tolerability. Presented at the World Psychiatric Association meeting. 2004.

  75. Comparisons of Response to Stimulant Preparations in Pediatric Epilepsy. Presented at the American Neurological Association meeting. 2004.

  76. Comparisons of Response to Stimulant Preparations in Pediatric Epilepsy. Presented at the American Academy of Child and Adolescent Psychiatry meeting. 2004.

  77. A Comparison of Divalproex, Gabapentin, and Oxacarbazepine in Aggressive Youth. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2004.

  78. Ziprasidone in Pediatric Patients: Efficacy and Tolerability. Presented at the New Clinical Drug Evaluation Unit (NCDEU). 2004.

  79. No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series. J Child Adolesc Psychopharmacol. 2004; 14(2):295-310. View Abstract

  80. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatry. 2003 Oct; 42(10):1227-33. View Abstract

  81. No Seizure Exacerbation from Ziprasidone in Youth with Comorbid Epilepsy and Psychiatric Disorders: A Case Series. Presented at that 16th European College of Neuropsychopharmacology Congress. 2003.

  82. Comparison of Divalproex and Gabapentin: Effectiveness in Aggressive Youth. Presented at the 16th European College of Neuropsychopharmacology Congress. 2003.

  83. An Open Trial of the Safety and Efficacy of Mirtazepine in Children and Adolescents with Social Phobia. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2003.

  84. An Open Trial of the Safety and Efficacy of Mirtazapine in Children and Adolescents with Social Phobia. Presented at the Society for Biological Psychiatry meeting. 2003.

  85. Use of a computer-based application in a pediatric hemodialysis unit: a pilot study. J Am Acad Child Adolesc Psychiatry. 2003 Apr; 42(4):493-6. View Abstract

  86. Depression Experience Journal: A computer-based intervention for families facing childhood depression. Available online: http://www.experiencejournal.com/depression. 2003.

  87. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex and their combination. Journal of the American Academy of Child & Adolescent Psychiatry. 2003; 42(10):1227-1233.

  88. Stimulant Effectiveness in Well Controlled Versus Poorly Controlled Pediatric Epilepsy. Presented at the Institue for Psychiatric Services. 2002.

  89. Risperidone Treatment in Pediatric Patients with Epilepsy: Systematic Review of Medical Records. Presented at the International Conference on Child & Adolescent Mental Health. 2002.

  90. Aggressive Youth on Divalproex: Effectiveness as Reviewed in Medical Records. Presented at the Meeting of the American Psychiatric Association. 2002.

  91. Risperidone Treatment in Pediatric Patients with Epilepsy: Systematic Review of Medical Records. Presented at the Society for Biological Psychiatry. 2002.

  92. Stimulant Effectiveness in Well Controlled Versus Poorly Controlled Pediatric Epilepsy. Presented at the Annual Boston Society of Neurology and Psychiatry Cobb Assembly. 2002.

  93. Stimulant Effectiveness in Well Controlled Versus Poorly Controlled Pediatric Epilepsy. Presented at the Harvard Consolidated Department of Psychiatry Research Day. 2002.

  94. Sertaline Treatment for Young Children: Systematic Review of Medical Records. Journal of Child and Adolescent Psychopharmacology. 2002; 12(4):294-5.

  95. Aggressive Youth on Divalproex: Effectiveness as Reviewed in Medical Records. Journal of Adolescent Health. 2002; 30(2):125.

  96. Future of technology to augment patient support in hospitals. Stud Health Technol Inform. 2002; 80:231-44. View Abstract

  97. A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol. 2002; 12(4):337-45. View Abstract

  98. Corticotropin releasing hormone increases apparent potency of adrenocorticotropic hormone stimulation of cortisol secretion. Med Hypotheses. 2001 Nov; 57(5):544-8. View Abstract

  99. Risperidone Treatment in Pediatric Patients with Epilepsy: Systematic Review of Medical Records. Presented at the Meeting of the American College of Neuropsychopharmacology. 2001.

  100. 3 Years of a Pediatric Psychopharmacology Electronic Medical Records System. Presented at the Meeting of the American Academy of Child and Adolescent Psychiatry. 2001.

  101. An Open Study of Sustained Release Bupropion in Adults with ADHD and Substance Use Disorders. Presented at the Meeting of the American Academy of Child and Adolescent Psychiatry. 2001.

  102. Illness-related concerns of mothers of children with congenital heart disease. J Am Acad Child Adolesc Psychiatry. 2001 Jul; 40(7):847-54. View Abstract

  103. Risperidone Treatment for Aggressive Preschool Children: Systematic Review of Medical Records. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2001.

  104. Nefazodone for Depression in Bipolar and Non-Bipolar Youth: Systematic Review of Electronic Medical Records. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2001.

  105. Method and system for displaying icons representing informational items stored in a database. 2001.

  106. Method and system for displaying icons representing informational items stored in a database. 2001.

  107. Corticotropin releasing hormone increases Apparent Potency of ACTH Stimulation of Cortisol Secretion. Medical Hypothesis. 2001; 57(5):544-548.

  108. Zora: A Pilot Virtual Community in the Pediatric Dialysis Unit. MEDINFO 2001. Proceedings of the 12th World Congress on Medical Informatics. 2001; 10:800-804.

  109. Cardiac Experience Journal: A computer-based intervention for families facing pediatric heart disease. Available online: http://www.experiencejournal.com. 2001.

  110. Zora: a pilot virtual community in the pediatric dialysis unit. Stud Health Technol Inform. 2001; 84(Pt 1):800-4. View Abstract

  111. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2001; 11(3):239-50. View Abstract

  112. Implementation of an electronic medical record system in a pediatric psychopharmacology program. Int J Med Inform. 2000 Jul; 57(2-3):109-16. View Abstract

  113. The experience journal: a computer-based intervention for families facing congenital heart disease. J Am Acad Child Adolesc Psychiatry. 2000 Jun; 39(6):727-34. View Abstract

  114. Olanzapine in the Treatment of Bipolar Disorder in Juveniles. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2000.

  115. Bupropion SR for Attention Deficit Hyperactivity Disorder (ADHD)in Adults with Bipolar Disorder (BPD)and ADHD. Presented at the New Clincal Drug Evaluation Unit (NCDEU) meeting. 2000.

  116. Zora: A Pilot Virtual Community in the Pediatric Dialysis Unit. Presented at the Pediatric Academic Societies and American Academy of Pediatrics Joint Meeting. 2000.

  117. Epilepsy in children and adolescents. Child Adolesc Psychiatr Clin N Am. 1999 Oct; 8(4):671-94. View Abstract

  118. Using 'off the shelf', computer programs to mine additional insights from published data: diurnal variation in potency of ACTH stimulation of cortisol secretion revealed. Comput Methods Programs Biomed. 1999 Mar; 58(3):227-38. View Abstract

  119. Interactive Storytelling Environments: Coping with Cardiac Illness at Boston's Children's Hospital. Proceedings of CHI'98, Association of Computing CHI'98 Machinery Special Interest Group in Computer-Human Interaction Conference. 1998; 603-609.

  120. Experience Journals: Using Computers to Share Stories About Illness and Medical Intervention. MEDINFO 98. Proceedings of the 9th World Congress on Medical Informatics. 1998; 1323-1327.

  121. Experience Journals: Using Computers to Share Stories About Illness and Medical Intervention. MEDINFO 98. Proceedings of the 9th World Congress on Medical Informatics. 1998; 1323-1327.

  122. Experience journals: using computers to share personal stories about illness and medical intervention. Stud Health Technol Inform. 1998; 52 Pt 2:1325-9. View Abstract

  123. Computer Modeling of Human Data Reveals CRH Increases the Potency of ACTH Effect on Cortisol and Rate of Cortisol Degradation With Differences in Sexually Abused Girls. Presented at the Harvard Consolidated Department of Psychiatry Research Day. 1997.

  124. Computer Modeling of Human Data Reveals CRH Increases the Potency of ACTH Effect on Cortisol and Rate of Cortisol Degradation With Differences in Sexually Abused Girls. Presented at the Dynamical Neurosciences Symposium at the Society of Neurosciences Meeting. 1996.

  125. A Neural Network Approach to Modelling Personality Development. Presented at the Dynamical Neurosciences Symposium at the Society of Neurosciences Meeting. 1996.

  126. Book Review of Child and Adolescent Depression: Clinical and Research Perspectives. New England Journal of Medicine. 1996.

  127. Transexuals: MCMI-II Severe Personality Disorder Incidence Depends on Setting and Sex. Presented at the Harvard Consolidated Department of Psychiatry Research Day. 1995.

  128. A Computer Simulation of the Hypothalamic-Pituitary-Adrenal Axis. Presented at the American College of Neuropsychopharmacology Meeting. 1994.

  129. A Computer Stimulation of the Hypothalamic-Pituitary-Adrenal Axis. Proceedings of the Annual Symposium on Computer Applications in Medical Care. 1994; 1010.

  130. Book Review of The Kaspar Hauser Syndrome of "Psychosocial Dwarfism": Deficient Statural, Intellectual and Social Growth Induced by Child Abuse. New England Journal of Medicine. 1994; 331(15):1031.

  131. A computer simulation of the hypothalamic-pituitary-adrenal axis. Proc Annu Symp Comput Appl Med Care. 1994; 1010. View Abstract

  132. Rates of Personality Disorders in Gender Dysphorics Using a Self Report Inventory, the MCMI-II. Presented at the XIII International Sympsium on Gender Dysphoria. 1993.

  133. Using neural networks to model personality development. Med Hypotheses. 1993 Aug; 41(2):123-30. View Abstract

  134. Testing the psychogenic vomiting diagnosis. Four pediatric patients. Am J Dis Child. 1991 Aug; 145(8):913-6. View Abstract

  135. Testing the Psychogenic Vomitting Diagnosis: Four Pediatric Patients. American Journal of Diseases of Children. 1991; 148(8):913-916.

  136. Postsynaptic localization of 5-HT1D receptor binding sites in human caudate. Exp Neurol. 1991 Jul; 113(1):28-30. View Abstract

  137. Serotonin receptor and reuptake sites: pharmacologic significance. J Clin Psychiatry. 1990 Apr; 51 Suppl:5-12; discussion 13. View Abstract

  138. Aphrodiesiology: History, Folklore and Efficacy. In: The Pharmacology and Endocrinology of Sexual Function. Handbook of Sexology; series editors, Money, J., and Musaph, H. 1988; 6:499-515.

  139. Reductions of Serotonergic Receptors in Alzheimer's Disease: An Autoradiographic Study. Abstract presented at the Meeting of the American Academy of Neurology, 1986. 1986.
BESbswy
BESbswy